NOVAVAX INC Available-for-sale Securities, Gross Unrealized Loss
NOVAVAX INC (NVAX) reported Available-for-sale Securities, Gross Unrealized Loss of $50.00 thousand for the 12-month period ending 2015-12-31, per its 10-K filed 2016-02-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss · last filed 2016-02-29
- NOVAVAX INC available-for-sale securities, gross unrealized loss for the quarter ending 2015-12-31 was $35.00K, a 40.00% increase year-over-year.
- NOVAVAX INC available-for-sale securities, gross unrealized loss for the quarter ending 2015-09-30 was -$19.00K, a 146.34% decline year-over-year.
- NOVAVAX INC available-for-sale securities, gross unrealized loss for the quarter ending 2015-06-30 was $8.00K.
- NOVAVAX INC available-for-sale securities, gross unrealized loss for the quarter ending 2015-03-31 was $26.00K.
- NOVAVAX INC available-for-sale securities, gross unrealized loss for fiscal 2015 was $50.00K, a 31.51% decline from fiscal 2014.
- NOVAVAX INC available-for-sale securities, gross unrealized loss for fiscal 2014 was $73.00K.
- NOVAVAX INC available-for-sale securities, gross unrealized loss for fiscal 2013 was $0.00.
| Period end | Available-for-sale Securities, Gross Unrealized Loss 3 month | Available-for-sale Securities, Gross Unrealized Loss 6 month | Available-for-sale Securities, Gross Unrealized Loss 9 month | Available-for-sale Securities, Gross Unrealized Loss 12 month |
|---|---|---|---|---|
| 2015-12-31 | $35.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $16.00K derived: sum of 2 quarters · filed 2016-02-29 | $24.00K derived: sum of 3 quarters · filed 2016-02-29 | $50.00K 10-K · filed 2016-02-29 |
| 2015-09-30 | -$19.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$11.00K derived: sum of 2 quarters · filed 2015-11-09 | $15.00K 10-Q · filed 2015-11-09 | $40.00K derived: sum of 4 quarters · filed 2016-02-29 |
| 2015-06-30 | $8.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $34.00K 10-Q · filed 2015-08-10 | $59.00K derived: sum of 3 quarters · filed 2016-02-29 | $100.00K derived: sum of 4 quarters · filed 2016-02-29 |
| 2015-03-31 | $26.00K 10-Q · filed 2015-05-07 | $51.00K derived: sum of 2 quarters · filed 2016-02-29 | $92.00K derived: sum of 3 quarters · filed 2016-02-29 | |
| 2014-12-31 | $25.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $66.00K derived: sum of 2 quarters · filed 2016-02-29 | $73.00K 10-K · filed 2016-02-29 | |
| 2014-09-30 | $41.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $48.00K 10-Q · filed 2014-11-06 | ||
| 2014-06-30 | $7.00K 10-Q · filed 2014-08-07 | |||
| 2013-12-31 | $0.00 10-K · filed 2015-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |